Cecilia Fernández Mateos1, Maria García-Uria2, Tomás Lucas Morante3, José García-Uría4. 1. Neurosurgery Department, Puerta de Hierro Hospital, Madrid, Spain. valdelagua@hotmail.com. 2. Emergency Medicine Department, Puerta de Hierro Hospital, Madrid, Spain. 3. Endocrinology Department, Puerta de Hierro Hospital, Madrid, Spain. 4. Neurosurgery Department, Puerta de Hierro Hospital, Madrid, Spain.
Abstract
PURPOSE: The goal of this study was to quantified the results of microsurgery, in all the patients with acromegaly treated by the same endocrinologist and the same surgeon between 1975 and 2015. METHODS: A series of 548 patients with acromegaly were operated and followed-up from 6 months to 40 years. Patients were selected according to five criteria: (1) Operated by the same surgeon. (2) No previous treatment. (3) Complete endocrinological preoperative studies including GH, OGTT, IGF-I, PRL test and TC/MRI. (4) Complete postoperative endocrinological evaluation for at least one determination of GH, OGTT, PRL test and IGF-I six months after surgery. (5) All the patients were supervised by the same endocrinologist. RESULTS: Microadenomas were present in 119 patients and 109 (91,5%) achieved remission. Non invasive macroadenomas were present in 200 patients and 164 achieved remission (82%). Results were worse for invasive macroadenomas but even with great invasions some patients achieved clinical remission. Follow-up range from 6 months to 40 years (mean 3.3 ± 2.3) A long term follow-up of 15 years was achieved in 61 patients. Four of them had a recurrence 4, 7, 8, 12 years after surgery (6.5%). There was not mortality and the rate of complications was low. CONCLUSIONS: Surgery remains the first line of therapy for a majority of acromegalic patients. This series proves to be very valuable in circumscribed adenomas but also in invasive tumours. Levels of GH and IGF-I were decreased in almost all the patients without remission.
PURPOSE: The goal of this study was to quantified the results of microsurgery, in all the patients with acromegaly treated by the same endocrinologist and the same surgeon between 1975 and 2015. METHODS: A series of 548 patients with acromegaly were operated and followed-up from 6 months to 40 years. Patients were selected according to five criteria: (1) Operated by the same surgeon. (2) No previous treatment. (3) Complete endocrinological preoperative studies including GH, OGTT, IGF-I, PRL test and TC/MRI. (4) Complete postoperative endocrinological evaluation for at least one determination of GH, OGTT, PRL test and IGF-I six months after surgery. (5) All the patients were supervised by the same endocrinologist. RESULTS: Microadenomas were present in 119 patients and 109 (91,5%) achieved remission. Non invasive macroadenomas were present in 200 patients and 164 achieved remission (82%). Results were worse for invasive macroadenomas but even with great invasions some patients achieved clinical remission. Follow-up range from 6 months to 40 years (mean 3.3 ± 2.3) A long term follow-up of 15 years was achieved in 61 patients. Four of them had a recurrence 4, 7, 8, 12 years after surgery (6.5%). There was not mortality and the rate of complications was low. CONCLUSIONS: Surgery remains the first line of therapy for a majority of acromegalicpatients. This series proves to be very valuable in circumscribed adenomas but also in invasive tumours. Levels of GH and IGF-I were decreased in almost all the patients without remission.
Authors: Peter G Campbell; Erin Kenning; David W Andrews; Sanjay Yadla; Marc Rosen; James J Evans Journal: Neurosurg Focus Date: 2010-10 Impact factor: 4.047
Authors: Gabriel Zada; Luigi M Cavallo; Felice Esposito; Julio Cesar Fernandez-Jimenez; Anastasia Tasiou; Michelangelo De Angelis; Tullio Cafiero; Paolo Cappabianca; Edward R Laws Journal: Neurosurg Focus Date: 2010-10 Impact factor: 4.047
Authors: Christoph P Hofstetter; Raaid H Mannaa; Lynn Mubita; Vijay K Anand; John W Kennedy; Amir R Dehdashti; Theodore H Schwartz Journal: Neurosurg Focus Date: 2010-10 Impact factor: 4.047
Authors: Laurence Katznelson; Edward R Laws; Shlomo Melmed; Mark E Molitch; Mohammad Hassan Murad; Andrea Utz; John A H Wass Journal: J Clin Endocrinol Metab Date: 2014-10-30 Impact factor: 5.958
Authors: Brandon P Galm; Colleen Buckless; Brooke Swearingen; Martin Torriani; Anne Klibanski; Miriam A Bredella; Nicholas A Tritos Journal: Pituitary Date: 2020-06 Impact factor: 4.107
Authors: Adriana G Ioachimescu; Talin Handa; Neevi Goswami; Adlai L Pappy; Emir Veledar; Nelson M Oyesiku Journal: Endocrine Date: 2019-11-01 Impact factor: 3.633